BVT Aktienanleihe MRK 28.06.2024/ DE000VU5VEG2 /
11/06/2024 19:44:54 | Chg.-0.010 | Bid19:59:35 | Ask20:00:17 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
95.890EUR | -0.01% | 95.990 Bid Size: 50,000 |
96.200 Ask Size: 10,000 |
MERCK KGAA O.N. | 180.00 - | 28/06/2024 | Call |
GlobeNewswire
14:15
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire
14:00
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA